12:28:00 EDT Wed 21 Oct 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:BMRN - BIOMARIN PHARMACEUTICAL - http://www.biomarinpharm.com12:28:00 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMRN - Q0.278.06·78.120.278.06+0.150.2254.419,8744,45577.91  78.80  77.46131.945  67.1012:07:4212:0015 min RT 2¢

Recent Trades - Last 10 of 4455
Time ETExPriceChangeVolume
12:07:42Q78.050.141
12:07:42Q78.050.146
12:07:42Q78.050.1494
12:07:42Q78.060.151
12:07:42Q78.060.15100
12:07:32Q78.030.12100
12:07:32Q78.030.1294
12:07:29Q78.030.121
12:07:22Q78.050.14100
12:07:22Q78.050.1417

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2020-10-21 12:00U:BMRNNews ReleaseDEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals Inc. (BMRN)
2020-10-17 18:22U:BMRNNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN
2020-10-15 16:45U:BMRNNews ReleaseROSEN, A TOP RANKED LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BMRN
2020-10-08 11:00U:BMRNNews ReleaseBMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020
2020-10-07 08:31U:BMRNNews ReleaseBioMarin, Pioneer in Rare Disease Treatments for Phenylketonuria (PKU), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq ® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU
2020-10-06 15:49U:BMRNNews ReleaseROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important Deadline in Securities Class Action – BMRN
2020-10-05 22:50U:BMRNNews ReleaseSHAREHOLDER ALERT: CLAIMSFILER REMINDS BMRN, BTU, NKLA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
2020-10-05 08:31U:BMRNNews ReleaseScientific Luminary and MacArthur Fellowship Winner, Kevin Eggan, Ph.D., Joins BioMarin as Head of Research and Early Development
2020-10-03 19:35U:BMRNNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical, Inc. of Class Action Lawsuit and Upcoming Deadline – BMRN
2020-10-03 14:00U:BMRNNews ReleaseLEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
2020-10-02 19:50U:BMRNNews ReleaseROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRN
2020-10-02 11:30U:BMRNNews ReleaseThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of BioMarin Pharmaceuticals Inc. (BMRN) Investors
2020-10-02 08:31U:BMRNNews ReleaseBioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307
2020-10-01 16:00U:BMRNNews ReleaseGlancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of BioMarin Pharmaceuticals Inc. (BMRN) Investors
2020-10-01 14:00U:BMRNNews ReleaseINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of BioMarin Pharmaceuticals Inc. (BMRN) on Behalf of Investors